Older age and high blood pressure in the pulmonary arteries raise the risk of complications with balloon pulmonary angioplasty (BPA), a second-line treatment for chronic thromboembolic pulmonary hypertension (CTEPH), a study suggested. If high blood pressure persists after surgery to remove the pulmonary arterial blood clots that cause…
Search results for:
Balloon pulmonary angioplasty, or BPA, can be an effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), a new study highlights. “Patients treated with BPA experienced improvement in functional class and exercise capabilities, with relatively low rates of procedure-related complications,” researchers wrote. The study, “Refined Balloon Pulmonary…
The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) after an episode of acute pulmonary embolism (PE) is likely underestimated, a study suggests. This occurs despite the high frequency of symptoms consistent with CTEPH, underscoring that an appropriate diagnostic work-up of CTEPH is rarely undertaken. The study, “CTEPH: a…
Over the past year, the team here at Pulmonary Hypertension News has brought you up-to-date coverage of the latest developments in research, care, and treatment related to pulmonary hypertension (PH). We hope to continue to be a resource for the PH community in the coming year. Here is a…
Infants with pulmonary arterial hypertension (PAH) who were put on Adempas (riociguat) after Revatio (sildenafil) and other therapies failed to control their symptoms showed improvements in lung and right heart function, according to data from a small study. They also had a reduction in high blood pressure…
A mean pulmonary artery pressure (mPAP) — blood pressure in the lungs — of less than 40 mmHg (millimeters of mercury) significantly increases the survival rate of patients with different subsets of pulmonary arterial hypertension (PAH), a study suggests. The successful outcome was achieved with an intensive therapeutic approach…
Balloon pulmonary angioplasty (BPA) is a safe and effective, minimally invasive treatment for people with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), according to a study from the U.K. The study describes the treatment of the first group of CTEPH patients to be treated with BPA.
Over the last year, Pulmonary Hypertension News has brought you the latest news about groundbreaking discoveries, treatment developments, clinical trials, and other events related to pulmonary hypertension (PH). As we look ahead to 2020, here are our top 10 most-read stories of 2019, with a summary of their significance for…
November is Pulmonary Hypertension Awareness Month, and this year, the Pulmonary Hypertension Association (PHA) is highlighting risk factors and symptoms associated with the disease. PHA’s social media campaign, titled “PHaces of Hope,” is based on stories from pulmonary hypertension (PH) patients and their caregivers, as well…
Pulmonary hypertension (PH) is a rare, life-threatening disease that occurs because of high blood pressure in the arteries of the lungs. The disease requires urgent medical intervention and lifestyle changes. When first diagnosed, patients and their family members and caregivers may have unanswered questions. Many want to know how…
A new meta-analysis assessing balloon pulmonary angioplasty (BPA) and Adempas (riociguat) for treating inoperable chronic thromboembolic pulmonary hypertension (CTEPH) found both treatment strategies to be well-tolerated, and able to improve exercise tolerance and the function of the circulatory system. The study with that finding, “Balloon…
Balloon pulmonary angioplasty reduces sleep apnea in chronic thromboembolic pulmonary hypertension (CTEPH) patients, according to a study. The observed improvements further correlated with a better mean pulmonary arterial pressure. The results from the study, “Balloon pulmonary angioplasty attenuates sleep apnea in patients with chronic thromboembolic pulmonary hypertension,” was…